The healthcare group Fresenius has made a decisive step in its restructuring: The company announced that it is selling a large portion of its shares in the rehabilitation business of its subsidiary Vamed. The private equity firm PAI Partners is acquiring 67 percent, while Fresenius retains 33 percent. The transaction, whose financial details were not disclosed, is expected to be completed in the second half of the year and is still subject to the approval of the Vamed general meeting.

This divestment is part of the strategic realignment launched by Fresenius last year, which from now on wants to focus on the stronger segments, Fresenius Kabi and Fresenius Helios. Vamed, previously a 77-percent subsidiary of Fresenius and no longer part of the core business, had recently struggled financially and had fallen into the loss zone early in the year.

The Sale of the Rehabilitation Business, Including 67 Facilities with 9,100 Beds and About 9,500 Employees Across Several European Countries, Valued at 853 Million Euros. It Generated Profits Last Year with Revenues of About 1 Billion Euros. Fresenius Emphasizes that the Rehab Business Holds a Strong Market Position, but Significant Investments are Needed to Fully Realize its Potential.

Michael Sen, the CEO of Fresenius, explained that the divestiture is a key measure for optimizing the portfolio and allows management to focus more on the core business and further reduce corporate complexity.

After the announcement of the plans, Fresenius shares rose temporarily by 0.79 percent to 28.19 euros in XETRA trading. This underlines the confidence of investors in the strategic realignment of the company.